Clinical results continue to lift Synairgen

0 mins. to read
Clinical results continue to lift Synairgen

Shares in AIM-listed drug researcher Synairgen (LON:SNG) climbed by 9.52% to 208.08p (as of 11:25 BST) today after it expanded on yesterday’s announcement of clinical trial results. Patients receiving Synairgen’s treatment during a phase II trial were twice as likely to recover from COVID-19 than those on a placebo. The company is working closely with regulators to bring this to market as soon as possible.

Further updates and data analyses will be made available in due course.

Comments (1)

Leave a Reply

Your email address will not be published. Required fields are marked *